1.Bioinformatic analysis of pygo1 gene in Homo sapiens.
Journal of Zhejiang University. Medical sciences 2014;43(4):453-457
OBJECTIVETo analyze the structure and function of PYGO1 protein with bioinformatics.
METHODSThe bioinformatic methods and tools were used to analyze the physical and chemical properties, transmembrane region, hydrophobicity and hyrdrophilicity, secondary structure and functional category of PYGO1 protein.
RESULTSThe bioinformatic analysis revealed that proline content was the highest of all amino acid residues in PYGO1 protein; the molecular formula was C(1943)H(2937)N(577)O(635)S(18) with a relative molecular mass of 45; and the theoretical isoelectric point was 6.38. The analysis also demonstrated that PYGO1 was a hydrophilic and non-transmembrane protein; its main component was alpha-helix and random coil; it contained a plant homeodomain.
CONCLUSIONHuman pygo1 gene may act as a transcription regulation factor to regulate the heart development and the progress of heart diseases.
Adaptor Proteins, Signal Transducing ; chemistry ; Amino Acid Sequence ; Computational Biology ; Humans ; Protein Structure, Secondary
2.Thalidomide in combination with interferon in the induction therapy for relapsed refractory T-cell lymphoma:two cases report and literature review
Xiaobing XU ; Xudong WEI ; Qingsong YIN ; Ping WANG ; Hao AI ; Ruihua MI ; Lin CHEN
Journal of Leukemia & Lymphoma 2015;24(10):595-597
Objective To observe the effectiveness and side-effect of two cases of relapsed and refractory T-cell lymphoma (TCL) treated with thalidomide and interferon.Methods Two cases of relapsed and refractory TCL was treated with thalidomide and interferon, the efficacy and side-effect were observed, and the relevant literature was reviewed.Results The patients achieved partially remission after being treated with thalidomide and interferon.Conclusion Thalidomide in combination with interferon can be used as a second line therapy for relapsed and refractory TCL.
4.Dasatinib combined with methotrexate and L-asparaginase in the treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukemia cause severe drug-induced liver injury: one case report and literature review
Lu WANG ; Xudong WEI ; Qingsong YIN ; Ping WANG ; Ruihua MI ; Hao AI
Journal of Leukemia & Lymphoma 2015;24(11):668-671,675
Objective To improve the cognition of sever liver injury of treating Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) with salvage chemotherapy of dasatinib combined with high-dose methotrexate (HD-MTX) and L-asparaginase (L-Asp).Methods Severe drug-induced liver injury caused by dasatinib with HD-MTX and L-Asp in one patient with Ph+ ALL was reported.Results Severe drug-induced liver injury happened on the seventh day after treatment,TBIL 221.7 μmol/L,DBIL 156.1 μmol/L,IBIL 65.6 μmol/L,ALT 111 U/L,AST 131 U/L,ALP 354 U/L,GGT 256 U/L,TBA 199.2 μmol/L.Through proper treatment,the patient recovered quite good,and the patient achieved complete remission after this chemotherapy.Conclusion Salvage chemotherapy which contains dasatinib,MTX and L-Asp can be effectively used in Ph+ ALL,but they are all of the hepatotoxicity,so drug-induced Liver injury may happen while they are used together.
5.The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate-or higer-risk myelodysplastic syndromes in the elderly patients
Hao AI ; Xudong WEI ; Qingsong YIN ; Ping WANG ; Ruihua MI ; Fangfang YUAN ; Lin CHEN ; Yongping SONG
Chinese Journal of Internal Medicine 2017;56(8):606-609
To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine regimen in patients with acute myeloid leukemia (AML) and intermediate-or higer-risk myelodysplastic syndrome (MDS).Of 6 AML cases,2 achieved complete remission (CR),2 with partial remission(PR),1 with stable disease(SD),1 with progressive disease(PD).As to the 8 MDS patients,one achieved CR and 6 with hematologic improvement (HI),1 case SD.Low dose subcutaneous decitabine regimen could be an alternative choice of older AML or MDS patients.
6.Detection on antiserum of Yersinia pestis phage in Marmota himalayana blood in the natural plague foci of Qinghai-Tibet Plateau
LI Cun-xiang ; WEI Bai-qing ; XIONG Hao-Ming ; ZHANG Ai-ping
China Tropical Medicine 2022;22(10):913-
Abstract: Objective To detect and analyze the antiserum of Yersinia pestis phage in Marmota himalayana blood from the natural plague foci of Qinghai-Tibet Plateau by micro-bolus technique, to provide a theoretical basis for interaction between phages and mammalian immunology, phage therapy and interaction between bacteriophage and ecology in future. Methods Using diagnostic Yersinia pestis phage and 3 wild plague phages from Qinghai-Tibet Plateau Natural Plague Foci as antigens, 847 serums of Marmota Himalayana blood, from Tongde, Guinan, Gonghe, Xinghai, Tianjun foci counties in Qinghai Plateau, were collected from July to September in 2020, 2021 and determined on antiserum of Yersinia pestis phage by microplate method and double agar plate method. Results The neutralization reaction experiment lasted for 24 hours between 4 phage and 847 serums by microplate method independently. These mixtures were tested by double agar plate method. All results were negative on antiserum of Yersinia pestis bacteriophage. Conclusions The positive antiserum of Yersinia pestis phage in Marmota himalayana were not found the natural plague foci of Qinghai-Tibet Plateau, which agreed with plague epidemiology in 5 foci counties in Qinghai plateau from 2020-2021, that was a characteristic of the resting period. In other words, it was in the absence of plague pathogen. It also showed indirectly that the absence or weak presence of Yersinia pestis bacteriophage in the plague foci. It showed a lower frequency on host animals coming into contact with phages naturally. The antiserum of Yersinia pestis phage may be related to the form of plague infection and the intensity of the disease.
8.Chloroplast genetic engineering: a new approach in plant biotechnology.
Tao SU ; Ya-Guang ZHAN ; Mei HAN ; Ai-Ping HAO
Chinese Journal of Biotechnology 2005;21(4):674-680
Chloroplast genetic engineering, offers several advantages over nuclear transformation, including high level of gene expression, increased biosafety, remedying some limitations associated with nuclear genetic transformation, such as gene silencing and the stability of transformed genes. It is now regarded as an attractive new transgenic technique and further development of biotechnology in agriculture. In this article we reviewed the characteristics, applications of chloroplast genetic engineering and its promising prospects were discussed.
Biotechnology
;
methods
;
Chloroplasts
;
genetics
;
Genetic Engineering
;
methods
;
Plants, Genetically Modified
;
genetics
;
Transformation, Genetic
10.Clinical observation of gefitinib in treatment of female patients with adenocarcinoma of lung WU
Xiao-Ping WU ; Ying-Zhi ZHUANG ; Hao JIANG ; You-Hua WU ; Wen-Xiang DAI ; Xiao-Hong AI ; San-Yuan TANG ;
Cancer Research and Clinic 2006;0(12):-
Objective To evaluate the efficacy and adverse effects of gefitinib in the treatment of fe- male patients with advanced adenocarcinoma of lung who had failed to previous chemotherapy.Methods These patients received 250mg of gefitinib orally,once daily until disease progression or development of intol- erable toxic reaction.They were evaluated one month after treatment and every other month thereafter.Results Among the 27 evaluable patients,there were 1 CR(3.7%),11 PR(40.8%),10 SD(37.0%)and 5 PD(18.5%). The overall response rate was 44.5%(95% CI 29%~68%);and 22 patients(81.5%)gained profit(CR+PR+ SD)from the clinical therapy(95% CI 62%~94%);the mean TTP was 7.2 months.Symptomatic improvement rate was 80.0%.The main adverse effects were mild rash and diarrhea.Conclusion gefitinib has significant efficacy in the treatment of female patients with advanced tung cancer who had failed to previous chemother- apy.Adverse effects are mild.gefitinib is a suitable therapy for these patients.